How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 11 Jul | 18 Jul | 25 Jul | 24 Aug | 28 Aug | 04 Sep | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 74.7 | 74.7 | 74.7 | 74.3 | 74.3 | 74.3 | -0.5 |
| Healthcare | 22.9 | 22.9 | 22.9 | 23.1 | 23.1 | 23.1 | +0.2 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 13.31% | 7 | 8 | 7 | 8 | 5 | — | +1.5% |
| LUPIN | Pharma | 7.25% | 3 | 10 | 10 | 7 | 9 | — | -11.1% |
| DIVISLAB | Pharma | 6.52% | 9 | 8 | 1 | 4 | 1 | — | +38.4% |
| CIPLA | Pharma | 6.03% | 4 | 3 | 6 | 4 | 7 | — | -3.9% |
| APOLLOHOSP | Healthcare | 5.30% | 9 | 5 | 5 | 2 | 2 | — | +0.4% |
| DRREDDY | Pharma | 5.01% | 2 | 2 | 6 | 10 | 9 | — | -14.7% |
| MANKIND | Pharma | 3.74% | 4 | 8 | 9 | 3 | 5 | — | -6.1% |
| SAILIFE | Healthcare | 3.62% | 9 | 10 | 5 | 9 | 1 | Leader | +27.8% |
| AJANTPHARM | Pharma | 3.41% | 8 | 10 | 1 | 3 | 3 | — | +13.9% |
| MAXHEALTH | Healthcare | 3.15% | 1 | 9 | 6 | 5 | 6 | — | -6.0% |
| MEDPLUS | Pharma | 2.69% | 2 | 4 | 5 | 4 | 7 | — | -27.0% |
| GLAXO | Healthcare | 2.66% | 8 | 7 | 2 | 8 | 4 | — | +31.0% |
| IPCALAB | Pharma | 2.57% | 9 | 5 | 1 | 3 | 4 | — | +14.3% |
| THYROCARE | Pharma | 2.51% | 7 | 10 | 8 | 9 | 2 | — | +1.4% |
| VIJAYA | Pharma | 2.42% | 7 | 10 | 5 | 4 | 1 | — | +10.1% |
| ABBOTINDIA | Pharma | 2.24% | 3 | 9 | — | 6 | 8 | — | -3.8% |
| GLAND | Pharma | 2.16% | 10 | 7 | 5 | 4 | 4 | Leader | +27.9% |
| PPLPHARMA | Pharma | 2.09% | 10 | 1 | 5 | 9 | 5 | Leader | +28.4% |
| LALPATHLAB | Healthcare | 2.05% | 7 | 8 | 7 | 5 | 3 | — | +18.6% |
| ALKEM | Pharma | 2.01% | 3 | 8 | 7 | 6 | 8 | — | -6.6% |
| NH | Healthcare | 1.80% | 5 | 8 | 7 | 10 | 4 | — | -4.9% |
| PFIZER | Healthcare | 1.65% | 5 | 7 | 1 | 8 | 7 | — | -2.9% |
| EMCURE | Pharma | 1.58% | 10 | 10 | 9 | 10 | 4 | Leader | +7.6% |
| AUROPHARMA | Pharma | 1.54% | 8 | 3 | 10 | 6 | 7 | — | +9.9% |
| SYNGENE | Healthcare | 1.46% | 1 | 2 | 6 | 7 | 7 | — | -17.8% |
| FORTIS | Healthcare | 1.37% | 4 | 8 | 5 | 5 | 6 | — | -12.4% |
| SANOFI | Pharma | 1.07% | 2 | 6 | 3 | 8 | 9 | — | -5.7% |
| AKUMS | Pharma | 1.00% | 8 | 3 | 4 | 2 | 3 | — | +33.9% |
| ANTHEM | Pharma | 0.92% | 10 | 10 | 6 | 3 | 1 | Leader | +16.3% |
| BIOCON | Pharma | 0.92% | 4 | 1 | 10 | 2 | 7 | — | -8.8% |
| ASTRAZEN | Pharma | 0.55% | 2 | 5 | 2 | 1 | 6 | — | -22.3% |
| INDOCO | Pharma | 0.43% | 10 | 2 | 4 | 6 | 6 | Leader | +21.2% |
| CONCORDBIO | Pharma | 0.17% | 8 | 4 | 2 | 5 | 3 | — | +16.2% |
Performance · 5.0y
Over the last 5.0 years ₹100 in the fund grew to ₹183 (+83%), vs ₹156 for Nifty 500 (+56%) and ₹137 for Nifty 50 (+37%). Its relative-strength line ended at 133 vs Nifty 50 and 117 vs Nifty 500 — above 100, sustained outperformance.